TS 35.46 Tenaris S.A. $TS Hit a 52 week low of 35.42

New Post Public Reply Private Reply Replies (0) Message Board
Emylers
TS 35.46 Tenaris S.A. $TS Hit a 52 week low of 35.42 Closing the day 10:45 at 35.46 -0.96 -2.64% With a day low of 35.42 and a total volume of 438,927.

TS Recent Posts: http://investorshangout.com/Tenaris-SA-TS-52890/

TS Tenaris S.A. Recent Headline News

17.6% Return Seen to Date on SmarTrend Tenaris Call (TS)
Comtex SmarTrend(R) - Tue Nov 18, 11:07AM CST
SmarTrend identified a Downtrend for Tenaris (NYSE:TS) on October 1st, 2014 at $44.35. In approximately 2 months, Tenaris has returned 17.62% as of today's recent price of $36.53.
TS: 35.50 (-0.92)

Earnings Look Back: Tenaris Is Down 4.1% Since Reporting Quarterly Results 1 Week Ago (TS)
Comtex SmarTrend(R) - Mon Nov 17, 8:12AM CST
When Tenaris (NYSE:TS) reported earnings 12 days ago on November 5th, 2014, analysts, on average, expected the company to report earnings of $0.59 on sales of $2.5 billion. Tenaris actually reported a break-even quarter on sales of $2.4 billion, missing EPS estimates by $0.59 and missing revenue estimates by $66.9 million. Since the company's report, shares of Tenaris have fallen from $38.45 to $36.87, representing a loss of 4.1% in the past 12 days.
TS: 35.50 (-0.92)

Shares of TS Down 16.9% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Nov 11, 9:54AM CST
SmarTrend identified a Downtrend for Tenaris (NYSE:TS) on October 1st, 2014 at $44.35. In approximately 1 month, Tenaris has returned 16.95% as of today's recent price of $36.83.
TS: 35.50 (-0.92)

Is it Time to Push Away From the Pinnacle Foods Buffet?
at The Street - Tue Nov 11, 5:10AM CST
With Pinnacle projected to grow earnings at a substantial rate, investors may wonder if it is time to leave the buffet line. Here are some juicy numbers to chew on.
SPY: 204.69 (-0.86), MDLZ: 38.83 (+0.14), HSH: 62.96 (unch), PF: 32.53 (+0.05), TS: 35.50 (-0.92), GIS: 51.65 (+0.06)

Tenaris' (TS) CEO Paolo Rocca on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 12:56PM CST

TS: 35.50 (-0.92)

Tenaris misses by $0.05, revenue in-line
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 6:16PM CST

TS: 35.51 (-0.91)

Tenaris Announces 2014 Third Quarter Results
Marketwired - Wed Nov 05, 3:46PM CST
Tenaris S.A. (NYSE: TS) (BAE: TS) (BMV: TS) (MILAN: TEN) ("Tenaris" today announced its results for the quarter and nine months ended September 30, 2014 with comparison to its results for the quarter and nine months ended September 30, 2013.
TEN: 55.99 (-0.69), TX: 19.53 (-0.12), TS: 35.51 (-0.91)

Tenaris Down 13.5% Since SmarTrend Downtrend Call (TS)
Comtex SmarTrend(R) - Tue Nov 04, 9:28AM CST
SmarTrend identified a Downtrend for Tenaris (NYSE:TS) on October 1st, 2014 at $44.35. In approximately 1 month, Tenaris has returned 13.52% as of today's recent price of $38.35.
TS: 35.51 (-0.91)

Valmont (VMI) Misses Q3 Earnings and Revenue Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 11:00AM CDT
Valmont's (VMI) third-quarter earnings and revenues missed the Zacks Consensus Estimate.
MRC: 21.29 (-0.51), VMI: 136.71 (-0.59), TS: 35.51 (-0.91), MWA: 9.51 (-0.31)

Why Manitowoc Company (MTW) Could Be Positioned for a Slump - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 7:47AM CDT
Manitowoc Company has witnessed a significant price decline in the past four weeks and negative earnings estimate revisions for the current quarter and the current year, making it time for investors to sell it off
MIDD: 91.84 (-1.29), WOR: 36.91 (-1.26), TS: 35.51 (-0.91), MTW: 20.87 (-0.10)

SmarTrend Watching for Potential Rebound in Shares of Tenaris After 1.81% Loss
Comtex SmarTrend(R) - Tue Oct 14, 5:02PM CDT
Tenaris (NYSE:TS) traded in a range yesterday that spanned from a low of $39.19 to a high of $40.85. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $40.10 on volume of 4.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
TS: 35.51 (-0.91)

Look for Shares of Tenaris to Potentially Rebound after Yesterday's 1.81% Sell Off
Comtex SmarTrend(R) - Tue Oct 14, 5:01PM CDT
Tenaris (NYSE:TS) traded in a range yesterday that spanned from a low of $39.19 to a high of $40.85. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $40.10 on volume of 4.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
TS: 35.51 (-0.91)

Earnings Reports to Refresh Market Views - Analyst Blog
John Blank - Zacks Investment Research - Mon Oct 06, 1:10PM CDT
This fall, "divergence" is the stock market’s mantra.
MRKT: 25.36 (+0.02), TS: 35.51 (-0.91)

Auto, Energy Fire Up Steel, But Euro Threat Is Rising
at Investor's Business Daily - Fri Oct 03, 3:53PM CDT
Until recently, Wall Street was pretty smitten with steel manufacturers. Companies ranging from industry maverick Nucor to the iconic U.S. Steel hit multiyear highs amid enthusiasm over the industry's recovery. That enthusiasm petered out in recent...
STLD: 22.24 (-0.58), F: 15.38 (-0.12), NUE: 53.57 (-0.79), AKS: 6.20 (-0.19), TS: 35.51 (-0.91), X: 34.62 (-1.38), MT: 12.31 (-0.14), PKX: 66.91 (-2.01)

Valmont (VMI) Slashes FY14 Earnings Outlook, Shares Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 1:20PM CDT
Valmont industries (VMI) has lowered its 2014 earnings guidance.
MRC: 21.29 (-0.51), VMI: 136.71 (-0.59), TS: 35.51 (-0.91), MWA: 9.51 (-0.31)

Tenaris Set to Possibly Pullback After Yesterday's Rally of 2.35%
Comtex SmarTrend(R) - Thu Sep 11, 4:00PM CDT
Tenaris (NYSE:TS) traded in a range yesterday that spanned from a low of $45.09 to a high of $45.91. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $44.92 on volume of 3.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
TS: 35.50 (-0.92)

After Yesterday's Rally of 2.35% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Sep 11, 3:58PM CDT
Tenaris (NYSE:TS) traded in a range yesterday that spanned from a low of $45.09 to a high of $45.91. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $44.92 on volume of 3.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
TS: 35.50 (-0.92)

Tenaris S.A. (TS) Stock Research Links

TS Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Swanson Nexus Pro Launch: Boost for Dietitians

Updated Category News Views 184

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...

Continue Reading
Alaska's Insurance Maze: Coverage Over Cheap Policies

Updated Category News Views 138

Beyond Premiums: Assessing Real Coverage Needs The Alaskan wilderness isn't just home to stunning views; it's also a land where insurance needs to go beyond the average cookie-cutter policy. You'd think the cheapest option would suffice, but that's where residents might trip into financial quicksand. Devery Prince, a seasoned insurance principal, sheds light on why...

Continue Reading
Ping An's Bold Green Moves Ahead of APEC 2026

Updated Category News Views 0

Ping An's Pitch for Green: Talking the Talk and Walking the Walk? Well, here's something cooking in Shenzhen at the Ping An Finance Center—an international seminar championing green development initiatives. It's all buzz around Ping An Insurance (HKEX: 2318; SSE: 601318) flexing its green muscle, orchestrating conversations right before APEC 2026. Talk about timing....

Continue Reading
Likang's Bold Move: Cancer Immunotherapy at AD Summit

Updated Category News Views 134

Cancer Care Takes Center Stage Kicking off with a bang in Abu Dhabi, Likang Life Sciences has made a splash in the world of personalized cancer immunotherapy. The Abu Dhabi Future Health Summit 2026 served as the backdrop for this bold move, lighting up discussions with their AI-enabled innovations. Likang's showing at the Summit wasn't just another walk in the park—it...

Continue Reading
Spooky Dining at CARNE: A Halloween Hit in Oxnard

Updated Category News Views 197

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Continue Reading
CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Updated Category News Views 204

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

Continue Reading
Apalutamide Boosts Outlook for Prostate Cancer Treatment

Updated Category News Views 69

Fresh Findings on High-Risk Prostate Cancer Treatments In an industry that often feels like a game of chess, Johnson & Johnson's recent news unveils another one of their strategic moves with the announcement of breakthrough results from their Phase 3 PROTEUS substudy. Turns out, ERLEADA®, their apalutamide treatment, isn't just another pawn; it's a potential...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 173

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
World Young Scientist Summit 2026 in Wenzhou Kicks Off

Updated Category News Views 154

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Continue Reading
Bio-Thera's New Data: A Game Changer for NSCLC?

Updated Category News Views 337

A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...

Continue Reading

Top 5 Most Recently Viewed Articles

BerGenBio Welcomes First Patient in Lung Cancer Study

Updated Category News Views 202

BerGenBio Embarks on Promising Lung Cancer Trial BerGenBio ASA, a clinical-stage biopharmaceutical company dedicated to combating serious diseases through innovative therapies, has reached a significant milestone in its journey. The company has successfully included the first patient in its clinical trial, focusing on the cutting-edge AXL kinase inhibitor known as...

Continue Reading
CIMG Inc. Introduces Tokenized Stock on FlowStocks Platform

Updated Category News Views 247

CIMG Inc. Introduces Tokenized Stock on FlowStocks Platform CIMG Inc. (NASDAQ: IMG), a dynamic group in the digital health and sales development sector, has officially launched its tokenized stock on the FlowStocks platform. This exciting development follows successful testing and represents a significant shift in how the company interacts with its investors. The new...

Continue Reading
Exploring the Impact of New SEC Leadership on Cryptocurrency

Updated Category News Views 179

New Era for Cryptocurrency Under SEC Leadership The recent changes at the Securities and Exchange Commission (SEC) under new leadership signal a transformative period for the cryptocurrency market. These developments could reshape the regulatory landscape, offering clarity and direction for investors and companies involved in the digital asset space. Understanding the...

Continue Reading
Shytoshi Kusama Transitions Roles: Shiba Inu's New Direction

Updated Category News Views 190

Shytoshi Kusama Transitions to New Leadership Role Shytoshi Kusama, the driving force behind the Shiba Inu ecosystem, has made a significant change by stepping down from his role as the lead visionary. This pivotal shift marks a transition to the position of lead ambassador, as he aims to spearhead global adoption more effectively. The Shift in Leadership Announcing his...

Continue Reading
BASF Shares Fall Following Proposed Dividend Cuts to Shareholders

Updated Category News Views 281

BASF (ETR:BASFN) just took a hit on its stock price after announcing some major shifts in its dividend policy. Shares plummeted by 2.9% to €44.035, all thanks to the company's new proposed minimum annual dividend of €2.25 per share for the upcoming 2024 business year. That’s a stark drop from the previous €3.40 per share they dished out in 2023—talk about making...

Continue Reading